Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Our latest clients all have the potential to grow significantly in the near and long-term future

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Jul 12, 2017 11:13 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jul 18, 2017 3:13 am

LXRP Presentation and Fact Sheet Now Available

16-page $LXRP Presentation Is Now Available Online:
http://www.networknewswire.info/lxrp/presentation

$LXRP Fact Sheet Is Now Available Online:
http://www.networknewswire.info/lxrp/factsheet
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jul 18, 2017 3:41 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Well-positioned For Expanding Canadian Cannabinoid Market

Lexaria Bioscience Corp. well-positioned for growth in expanding Canadian cannabinoid market
Canadian market for cannabis extracts and oils expected to top C$1.6 billion by 2020
Company’s patented technology infuses organically sourced hemp oil into molecules of other substances such as lipids, the basis of the human endocannabinoid system
Patented technology enables better-tasting hemp oil-infused gourmet food products with improved bioavailability of cannabinoids
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth in the emerging Canadian cannabinoid market. Lexaria is an innovative revenue-generating company developing and out-licensing proprietary technology for delivering bioactive compounds including cannabinoids.

With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in Canada and elsewhere work to research and develop healthy cannabinoid products. Investment capital in these “plant-to-bloodstream” companies is expected to grow exponentially. As a first mover into this space, Lexaria is well-positioned for increasing market share and revenue.

While cannabinoids such as cannabidiol (CBD) and THC boast a wide range of health benefits, they are poorly absorbed by the human gastrointestinal tract. Lexaria’s products take advantage of the company’s patented technology to offer health-conscious consumers improved absorption and taste of orally-ingested products. Lexaria’s lipophilic enhancement technology is proven to enhance the bioavailability of orally-ingested cannabinoids, thus allowing for lower dosages.

The company is in discussions for or has already signed B2B agreements with companies in Canada, the largest-market states in the U.S., and internationally. Lexaria has also developed its own brands using its patented technology to infuse hemp oil ingredients within lipids in foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

Lexaria continues research and development, signing a collaborative research agreement with the National Research Council of Canada (NRC) in February 2017 to investigate new opportunities in bioavailability enhancement of lipophilic active ingredient compositions. The company believes its patented technology can be utilized for the delivery of nicotine, vitamins, analgesics and a variety of other substances.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jul 18, 2017 3:44 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Awarded Australian Patent Protecting Cannabis Infused Edibles

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that the Australian Patent Office has granted patent #2015274698, which protects Lexaria’s method of improving absorption, speed of onset and taste of cannabinoid active agents in edible products. The term of the patent is 20 years from June 10, 2015. “We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles utilizing our technology in Australia,” Chris Bunka, CEO of Lexaria, stated in the news release. “This patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will seek additional licensing and product distribution partnering opportunities.” This morning’s announcement follows the award of a similar patent in the United States in October 2016. Lexaria intends to continue developing and solidifying its patent portfolio through the balance of 2017 and 2018.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Jul 21, 2017 3:23 am

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Commences Lab Work with National Research Council of Canada*

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced the start of laboratory work under its collaborative research project with the National Research Council of Canada (“NRC”). “We are delighted to have commenced formulation development and characterization work together with the NRC,” John Docherty, president of Lexaria Bioscience, stated in the news release. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.” Moving forward, several studies will be initiated in an effort to optimize Lexaria’s patented technology enabling delivery of lipophilic active agents within foods, beverages, capsules and other ingestible formats. Per this morning’s update, practical applications of this work could include further broadening or strengthening of Lexaria’s intellectual property portfolio and may also provide the foundation for new commercial arrangements.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jul 25, 2017 5:34 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Patented Cannabinoid Delivery System Approved

- Patented lipophilic delivery system increases bio-absorption
- Patents cover broad range of lipophilic bio-actives, including cannabinoids, vitamins, other pharma
- 19 patents filed across 44 countries
- First international patent issued and approved in Australia

Any argument over the efficacy of medicinal marijuana is settled science. Recent prestigious clinical studies have provided conclusive evidence that medical cannabinoids are effective medicine for a variety of diseases and ailments (http://nnw.fm/7HnBi). However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is simply excreted by the body. Subsequently, onset times and effectiveness vary wildly.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has patented and licenses a novel delivery system which infuses organically sourced hemp oil into the molecules of other substances. The system utilizes lipids, which form the basis of the human endocannabinoid system, increasing both absorption and bioavailability of payload molecules. Lexaria’s lipophilic enhancement technology increases the bio-absorption of cannabinoid edibles by five to 10 times, to roughly equal that of inhalation. The onset times for effectiveness are also reduced by about 75 percent due to rapid bio-absorption by bypassing first-pass liver metabolism. Not only does Lexaria’s methodology dramatically increase effectiveness; it also masks the taste of cannabinoids and eliminates the need for sugar additives.

Lexaria currently has 19 patent applications filed in the U.S. and internationally covering 44 countries. The patents encompass a broad range of lipophilic bio-actives including NSAIDs and Nicotine, as well as food/carrier that can be formulated and delivered using Lexaria’s technology. With U.S. patents already issued, the company announced just last week that its first international patent was accepted and issued in Australia (http://nnw.fm/4h0oA). This development opens the door for Lexaria to bring the Australian cannabinoid edibles market under its umbrella.

Chris Bunka, CEO of Lexaria, stated in the news release. “We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles utilizing our technology in Australia…(the) patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will seek additional licensing and product distribution partnering opportunities.”

Lexaria employs a low-cost, high-margin license and royalty model of revenue generation. By out-licensing to third party partners, the company keeps five to 10 percent of each partner’s gross sales. With multiple royalty agreements already in the works, the company will continue to expand its licensing network as it receives patent approvals. Interestingly, Lexaria’s novel technology has implications across a wide swath of consumer and pharmaceutical delivery protocols. The global impact of Lexaria’s patents and business model will easily reverberate to the bottom line and has only just begun.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Jul 27, 2017 4:02 pm

Biotech Players Lead the Growth Charge in the Legal Cannabis Market

NetworkNewsWire Editorial Coverage: The backbone of medical advancement is biotechnology, an industry wrought with the incredible potential of novel drug R&D, but vulnerable to the risk of stringent regulatory approval processes. Within this volatile market, however, is the cannabis-biotech sub-sector – a market flourishing with opportunity, innovation, and deep roots of medical possibilities. Fueled by an increasing volume of supportive research, cannabis-based biotech companies are addressing large markets of unmet medical need while rising to meet global demand of epic proportion. Included among several companies in the cannabis-biotech sub-sector is Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (LXRP Profile), a company emerging as a recognizable name within a space occupied by companies like GW Pharmaceuticals PLC (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Insys Therapeutics, Inc. (NASDAQ: INSY) and Axim Biotechnologies Inc. (OTCQB: AXIM).

Because the cannabis-biotech sub-sector remains in relative infancy, it is full of uncharted territory and prospects as companies aggressively explore the medicinal potential of marijuana and the plant’s compounds and applications. Food bioscience company Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX), for instance, enjoys a unique position in this sub-sector. As the only publicly traded company with a cannabis-based intellectual portfolio that includes NSAIDs, nicotine and vitamins, Lexaria has multiple patents pending in over 40 countries, and it recently received its first patents in the U.S. and Australia relating to edible forms of cannabinoids (http://nnw.fm/e8LvY).

At the center of these patents is the company’s proprietary technology, which improves the delivery of bioactive compounds, primarily cannabinoids, into the human body. While cannabinoids tout great potential for medical treatment, the compounds are poorly absorbed by the gastrointestinal tract. As a result, users frequently turn to alternative administration methods, like smoking, for enhanced effectiveness. Lexaria’s lipophilic enhancement technology, however, demonstrates the ability to boost bioavailability of orally-ingested cannabinoids while at the same time masking their “unusual” taste. This technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids. Other patents are also pending for tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

In collaboration with the National Research Council of Canada (“NRC”) (http://nnw.fm/fdG8Z), Lexaria has commenced lab work to study and optimize the application of its technology toward enabling the delivery of lipophilic active agents within foods, beverages, capsules and other ingestible formats. Practical applications of this collaboration could include expansion of Lexaria’s IP portfolio and the possibility of new commercial arrangements. Lexaria currently has two distinct consumer brands that utilize this game-changing technology of infusing hemp oil inside the lipids in foods: ViPova™ and Lexaria Energy.

Introduced in 2015, the ViPova product line began with a Chinese black tea containing hemp oil infused into dried, evaporated nonfat milk. The following year, Lexaria took advantage of the broader beverage market, and ViPova’s product line was expanded to include coffee and hot chocolate. The company sells its ViPova product directly online to consumers.

Lexaria Energy products also utilize the company’s patented infusion technology to deliver federally legal hemp oil ingredients inside nutritious and tasty formulations that are free of the bitter taste typically associated with hemp. Products in this line include the Lexaria Energy Bar, a hemp oil-infused protein bar. Other nutritious products are in development for the Lexaria Energy line, with a focus on ensuring responsible production techniques and gluten-free formulations.

Lexaria also licenses its technology to third-party partners, making royalties an integral part of its overall business strategy and revenue potential as it pursues opportunities to broaden and strengthen its IP portfolio. Because Lexaria’s technology relies on a delivery methodology – and not just a single drug or molecule – even cannabis giants like GW Pharmaceuticals PLC (GWPH) might discover Lexaria’s technology as an effective way to deliver its drug.

GW Pharmaceuticals has become a world leader in developing plant-derived cannabinoid therapeutics by leveraging its established drug discovery and development processes, extensive intellectual property portfolio, and regulatory and manufacturing expertise. The company’s research delves into the potential therapeutic applications of cannabinoids, and GW has evaluated the pharmacology of various cannabinoids across a broad array of disease areas. GW’s focus is chiefly on central nervous system disorders, including epilepsy. The company’s lead product candidate, Epidiolex, is a liquid formulation of pure plant-derived CBD and is in development to treat various rare childhood-onset epilepsy disorders. GW has also commercialized Sativex, the world’s very first plant-derived cannabinoid prescription drug, which has been approved in 29 countries outside the U.S. for the treatment of multiple sclerosis-related spasticity. GW’s pipeline of other cannabinoid product candidates includes compounds in development for treating epilepsy, glioma and schizophrenia.

Another biotech standout in the cannabis market is clinical-stage pharmaceutical company Zynerba Pharmaceuticals, Inc. (ZYNE). Zynerba is focused on the development of innovative transdermal synthetic cannabinoid treatment options for patients with high unmet medical needs. The company’s development pipeline includes two lead product candidates that are being evaluated in five therapeutic indications: ZYN002 and ZYN001. Currently in phase 2 clinical development for refractory epilepsy, osteoarthritis of the knee and Fragile X syndrome, ZYN002 is the first and only synthetic form of CBD and has been formulated as a patent-protected permeation-enhanced gel for transdermal delivery into the circulatory system. ZYN001 is a THC pro-drug that enables transdermal delivery through the skin and into the circulatory system via a patch. A phase 1 clinical program for fibromyalgia and peripheral neuropathic pain was initiated by Zynerba in the first half of 2017.

Specialty pharmaceutical company Insys Therapeutics, Inc. (INSY) is focused on developing and commercializing innovative drugs and novel drug delivery systems for therapeutic molecules with the end goal of improving quality of life for patients. Insys uses proprietary sublingual spray technology along with its pharmaceutical cannabinoid development capabilities to address the clinical inadequacies of existing commercial products. In May 2017, Insys Therapeutics received FDA approval for the final product label of its Syndros (dronabinol) oral solution, marking the last regulatory step needed before the official launch of the product, which is planned to take place sometime in August 2017. Syndros is a liquid formulation of the pharmaceutical cannabinoid dronabinol and has been approved for use in the treatment of weight loss-related anorexia in AIDS patients and nausea and vomiting in chemotherapy patients who are unresponsive to conventional antiemetic treatments. Insys is additionally at the phase 2 clinical development stage for a cannabidiol treatment to address severe pediatric epilepsies.

Biotechnology company Axim Biotechnologies Inc. (OTCQB: AXIM) is a leader in cannabinoid R&D and is striving to set the green standard for cannabinoid bioscience. The company’s most advanced program is its phase 2 clinical trial of CanChew Plus chewing gum to treat irritable bowel syndrome. The company is similarly using a chewing gum-based approach for the treatment of pain, multiple sclerosis spasticity and other indications. CanChew Gum is the world’s first patented, functional chewing gum that is derived from CBD-rich industrial hemp, and it is legal in all 50 states. Axim is additionally conducting research into the use of molecularly-modified cannabinoids as neuroprotectants, as well as the use of industrial hemp-derived formulations of cannabigerol (CBG) for dermatological applications. AXIM is further conducting trials or has products in development targeting a large number of indications, including ADHD, smoking cessation, ulcerative colitis, Crohn’s disease, drug-related psychosis, psoriasis, atopic dermatitis and more. The company is also in the process of developing a unique extraction and freeze-drying technology for producing molecularly/genetically-controlled pharma-grade cannabinoids extracted from industrial hemp.

For biotech investors looking at the legal cannabis sector and interested in potentially taking part of the growth in the broader marijuana industry, the companies described above are all worth keeping on your investment radar. Stay tuned to NetworkNewsWire for more public information on investment opportunities and on Lexaria Bioscience.

For more information on Lexaria Bioscience, please visit: Lexaria Bioscience Corp. (LXRP)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Jul 28, 2017 6:10 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (LXRP) Well-Positioned for Growth as First Mover in Canada’s Cannabinoid Market

Among players in Canada’s emerging cannabinoid market, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth. Lexaria is a revenue-generating company engaged in developing and out-licensing proprietary technology for delivering bioactive compounds, including cannabinoids, and the company’s products utilize this patented lipophilic technology, which has been proven to enhance the bioavailability of orally ingested cannabinoids and also improve their taste.

“With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in Canada and elsewhere work to research and develop healthy cannabinoid products. Investment capital in these “plant-to-bloodstream” companies is expected to grow exponentially. As a first mover into this space, Lexaria is well-positioned for increasing market share and revenue.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Jul 31, 2017 4:25 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Set to Benefit as Study Shows More Benefits of Cannabidiol

- Cannabidiol (CBD) combats anxiety, inflammation, nausea and vomiting
- Low side-effect profile means high doses of cannabidiol can be used for treatment of schizophrenia, dementia, diabetes and nausea
- Lower doses promote and maintain health with anti-oxidative, anti-inflammatory and neuroprotective effects
- Lexaria Bioscience Corp. set to benefit from increasing interest in CBD as patented technology improves taste, rapidity and effectiveness of bioactive compounds including cannabinoids

A new scientific review of the safety and side effects of cannabidiol confirms and expands on the myriad known health benefits of cannabidiol and the compound’s lack of side effects.

The review, titled “An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies,” was published in the journal Cannabis and Cannabinoid Research in June. To view the full publication, visit: http://nnw.fm/cbd-clinical-overview-pdf.

Cannabidiol has a number of beneficial effects, the study states; it is anti-inflammatory, anxiolytic, antiemetic and antipsychotic. This can only increase the demand for cannabidiol (CBD) products and is good news for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria has patented a revolutionary lipophilic delivery method which allows accurate, timely delivery of cannabinoids without the need for users to smoke, vape or otherwise inhale the substance.

Lexaria out-licenses its proprietary technology for improved taste, increased speed and efficiency in the delivery of bioactive compounds, including cannabinoids. The special manufacturing process infuses CBD within lipids, which form the basis of the human endocannabinoid system. Lexaria Bioscience’s new process masks the undesirable taste of cannabidiol, which eliminates the need for added sugar and results in a healthier product.

The review’s authors, Iffland Kerstin and Grotenhermen Franjo, concluded that along with the beneficial effects, the safety profile of CBD is excellent. Chronic use and high doses of up to 1,500 mg per day have repeatedly shown to be well tolerated. Cannabidiol does not alter physiological parameters such as heart rate and blood pressure and does not adversely affect psychological and psychomotor functions, food intake or gastrointestinal transit.

The study’s authors reviewed clinical data and animal studies to extend and update a comprehensive survey by Bergamaschi et al. in 2011 on CBD safety and side effects; they concluded that CBD has a much better side effect profile than other drugs used for the treatment of epilepsy and psychotic disorders.

Several studies have shown cannabidiol to be effective in the treatment of epilepsy. In one study, CBD treatment reduced seizures by 45% in 261 young children who were not receiving relief from standard medications. In another study, CBD reduced the frequency of seizures by 39% in therapy-resistant epilepsy patients.

Cannabidiol has also been shown to have anti-anxiety effects equivalent to a standard dose of imipramine, a selective serotonin reuptake inhibitor sold as Tofranil and commonly used to treat anxiety and depression.

Studies have found that CBD reduces inflammation in the gastrointestinal system, treats symptoms of multiple sclerosis and helps with the management of glaucoma.

According to the study review, cannabidiol has also been shown to:

- help with cannabis withdrawal
- reduce heroin-seeking behaviors
- reduce psychotic symptoms in Parkinson’s patients
- reduce the likelihood of developing diabetes
- positively modulate the immune system in diseases such as multiple sclerosis, arthritis and diabetes
- reduce amyloid beta neuro-inflammation and prevent the development of a social recognition deficit in Alzheimer’s disease.
- reduce swelling and inflammation in arthritis
- prevent or slow the spread of certain types of aggressive cancer cells
- reduce weight gain
- reduce symptoms of psychiatric disorders such as psychosis and bipolar disorder

Cannabidiol is not the only substance which can be formulated and delivered via Lexaria’s revolutionary delivery method; the patented technology can be used for delivery of nicotine, vitamins, analgesics and a variety of other substances. Tests by an independent, third-party lab show that Lexaria’s technological process and lipid formulation improve intestinal absorption by as much as 500%.

Patents have been issued to the company in the U.S. and Australia protecting Lexaria’s intellectual property for the edible delivery of all non-psychoactive cannabinoids, including cannabinoid edibles. A variety of food and beverage formats are protected by the patent, including tea, coffee, cocoa powder, fresh foods and meats, dairy products, pastas, breads, seeds, nuts, spices, herbs, candies, flavorings and more.

Lexaria is primarily a B2B enterprise, and it is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the U.S., and abroad.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Aug 01, 2017 4:34 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Sees New Round of Investors Attracted to Cannabis Market

- Has patents in the United States and Australia and patents pending in more than 40 countries for proprietary technology easing how edible cannabinoids enter body
- Revenue stream comes from own products and 5-10% margin of gross sales from licensing technology to third parties
- Signed C$250,000 joint venture agreement with National Research Council (NRC) in Canada to research and find best methods for processing active agents in foods

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) already owns international patents for its proprietary intellectual property and has more global patents pending in the cannabis marketplace. It believes that the sub-sector of bioscience technology for edible CBDs will expand. It expects a new round of investors will be attracted to “plant-to-bloodstream” companies. Initially, it said, investors funded “seed-to-plant” companies.

The Kelowna, British Columbia, Canada-based food bioscience company is a technology disruptor for edible CBDs. It markets a high absorption hemp oil formula, protein energy bars, exotic teas and high absorption hemp oil capsules to help the human body absorb CBDs. In its June 2017 corporate presentation for investors (http://nnw.fm/t8NXO), Lexaria Bioscience noted that its focus is on researching and developing additional products for the edible cannabinoids market. It owns international patent rights and has pending patents for its technology changing the way cannabinoids enter the body.

This sub-sector is in its relative infancy as companies seeks to learn more about the medicinal potential for medical marijuana. Lexaria Bioscience is the only publicly traded company which has intellectual property in this sub-sector, covering non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins, according to a July 2017 market research report titled, “Biotech Players Lead the Growth Charge in the Legal Cannabis Market” (http://nnw.fm/lpeU8). The company has received for its proprietary technology its first patents in the United States and Australia and has patents pending in more than 40 countries globally.

Lexaria’s technology aims to improve the human body’s absorption of CBDs in the gastrointestinal tract. The process is effective, not just for CBDs, but also for other non-psychoactive cannabinoids. Patents are pending, too, for NSAIDs, nicotine and other molecules, per the research report.

By masking the bitter taste, reducing ingestion time and improving bio-absorption of CBD products, Lexaria Bioscience enjoys revenue streams from its own product line brands, such as Turbo CBD™, ViPova™, and Lexaria Energy Foods, as well as from licensing to third party partners at a 5-10% margin of gross sales.

Lexaria Bioscience has also just signed a C$250,000 collaborative research agreement with the National Research Council (NRC) of Canada for an 18-month term to investigate opportunities to evaluate and determine the best methods for processing lipophilic active agents within foods. The research will also study cannabinoids such as THC, vitamins, nicotine and NSAIDs. The result could be isolating a chemical or physical “fingerprint” identification to study Lexaria’s technology in consumer products, the company’s investor presentation said.

For more information, visit the company’s website at http://www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Aug 02, 2017 4:08 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Spotlighted by Technical420

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, including cannabinoids, was recently spotlighted in an article on Technical420.com. The publication highlighted, in detail, several of the company’s key developments and growth catalysts. “During the last few months, Lexaria has improved its fundamental story through the following developments: 1) The company applied for a new patent from the U.S., 2) Lexaria has advanced its agreements and launched new businesses, 3) Expands its Reach into Asia, 4) Focused on R&D with major organizations, and 5) The company’s cash position has improved significantly and has fully funded new initiatives.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Aug 03, 2017 3:38 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Technology Offers More Potent Delivery of Cannabinoids

- Technology that improves bioavailability of orally ingested cannabinoids
- Safer approach that mitigates risks from carcinogens
- Generates revenue by out-licensing its technology internationally

Announcement of a new government initiative to reduce the level of nicotine in cigarettes to nonaddictive levels is good news for Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP). Less addictive cigarettes mean less dependence on smoking as a delivery system, not only for nicotine but other substances like cannabinoids, which is why the folks at Lexaria are cheering the Food and Drug Administration (FDA) on. This innovative bioscience company has developed technology that offers a safer and more efficient delivery system for bioactive compounds, including cannabinoids.

The idea of reducing nicotine levels has been knocking around for a while. Writing in the New England Journal of Medicine in 1994, Dr. Neal Benowitz, a professor of medicine at the University of California, San Francisco, proposed the idea, according to Scientific American (http://nnw.fm/3am8E). Lower levels of nicotine might make smoking less of a habit and so reduce the toll of the many carcinogens (cancer-causing agents) found in tobacco smoke. Less nicotine would also reduce the risks associated with nicotine itself. The substance is highly addictive, and heavy long-term use may damage arteries, increasing the risk of stroke. Nevertheless, the dangers posed by its use pale in comparison to those caused by the arsenic, benzene, lead and other carcinogens that permeate tobacco smoke.

In 1994, though, the FDA did not have the authority to set nicotine levels for cigarettes. That changed after the passage of the Tobacco Control Act in 2009, which gave the agency power to reduce, but not eliminate altogether, the amount of nicotine in cigarettes. Now, the FDA is exercising its mandate. Its new commissioner, Scott Gottlieb, believes that by making smoking less addictive, more Americans will buck the habit and avoid the peril of developing cancer. In addition, reduced nicotine levels in cigarettes may ultimately cause a divorce from smoking. After all, there are a variety of alternative ways to ingest nicotine, including vaping and chewing gum.

If the smokescreen is removed from cigarettes, they will be seen for what they are: simply, a hazardous delivery system for nicotine, albeit an effective one, no doubt. And for those who must have their nicotine, there are much safer ways to get it, an argument that applies equally well to cannabinoids. Lexaria has proprietary technology for improved delivery of bioactive compounds, which offers a no-smoking safer way to administer cannabinoids.

The company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, a decided advantage, since cannabinoids are not absorbed very well by the body’s gastrointestinal tract. The Lexaria process improves bio-absorption of cannabinoids to levels that equal smoking, and onset has been reported as occurring within 15-20 minutes, as opposed to 60-120 minutes for edibles. The company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for delta-9-tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

The Lexaria technology, which also improves taste, has the potential to improve the absorption and potency of a variety of medical products, including vitamins and analgesics. The company plans to generate revenue by out-licensing its technology internationally.

For more information, including a stock chart and videos, please visit www.LexariaEnergy.com/investors
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Aug 08, 2017 4:42 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Praised in Technical420 Article

- Lexaria Bioscience Corp. featured in a Technical420 article praising the company’s recent developments
- Lexaria is improving and strengthening patent portfolio; 19 patent applications are pending in more than 40 countries
- Company executes partnership with NeutriSci International; joint venture allows LXRP to enter Asian market

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), an innovative company licensing proprietary technology for the delivery of bioactive compounds including cannabinoids, is a “plant-to-bloodstream” company expected to draw investors in the cannabis marketplace. Lexaria has patented and licenses a novel delivery system that infuses organically sourced hemp oil into the molecules of other substances.

Cannabidiol, noted for its anti-inflammatory, anxiolytic, antiemetic and antipsychotic effects, is just one of several compounds targeted by Lexaria for its unique oral ingestion technology, which allows more efficient delivery of bioactive substances via oral ingestion without the need for unhealthy inhalation or the addition of sweeteners commonly used to mask bitter tastes. Non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins are among the substances targeted by Lexaria’s new delivery method.

A recent article in Technical420 (http://nnw.fm/0IT6s), a provider of research and analysis of cannabis stocks, praised the company for several positive developments over the past few months.

Lexaria has 19 patent applications filed and pending in more than 40 countries worldwide. The company strengthened its intellectual property portfolio with its first U.S. patent, issued in October 2016. The patent protects Lexaria’s intellectual property for infusion of cannabinoid compounds in edible products. Lexaria’s unique process improves the taste and bioavailability of cannabinoid food ingredients.

Another strong development is Lexaria’s joint venture with NeutriSci International (TSX.V: NU), a Canadian public company, to produce and sell a line of healthy edible cannabinoid products. The two companies will produce a line of cannabinoid mouth-melt products using Lexaria’s technology and NeutriSci’s proprietary pterostilbene tablet. Pterostilbene is an antioxidant that’s chemically similar to Resveratrol – a natural compound found primarily in blueberries and Pterocarpus marsupium heartwood, according to the U.S. National Library of Medicine (http://nnw.fm/Euz95).

The joint venture will operate as Ambarii Trade Corporations, and initial operations will be funded equally by Lexaria and NeutriSci. AMbarii’s plans include securing licensees in Canada, California and Colorado to produce mouth-melt products containing THC.

Lexaria is also venturing into the Asian market, as noted by the Technical420 article. Ambarii has entered into an LOI with Naturally Splendid Enterprises Ltd. (TSX.V: NSP) for production and distribution of the company’s sublingual full spectrum cannabidiol tablets in Japan and South Korea. With a population of 127 million, Japan is one of the world’s largest markets, and hemp oil containing cannabidiol is already legal in Japan. South Korea, with a population of 50 million, is expected to open its markets to hemp oil-sourced cannabidiol soon.

Lexaria will begin in vitro absorption studies to quantify improvements in absorption in human intestinal tissue and will conduct animal studies on whole-body reactions to the rapid and efficient delivery of cannabinoids, vitamins, NSAIDs and nicotine. Edible nicotine products could allow a healthier alternative to smoking, patches and nicotine gum. The article points out that the company’s R&D budget is fully funded from existing capital.

Lexaria has an improved cash position and an attractive valuation, the Technical420 article states, due to improved balance sheets and a much smaller warrant overhang. The company raised more than $1.7 million in April, and, from November 2016 through May 2017, the company raised more than $4 million in equity. Technical420 is “favorable” on these developments and expects to see significant advancement by Lexaria Bioscience.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Aug 10, 2017 4:26 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Discusses Company’s Progress in Interview

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced that its chief executive officer, Chris Bunka, was featured in a recent interview on the Uptick Network Stock Day Radio Show. Bunka leveraged the platform to discuss Lexaria’s overall accomplishments in the past three months, as well as the company’s expectations for profitability moving forward. He notes that ongoing research and development programs could open both the NSAID and Nicotine markets to Lexaria, providing an opportunity to significantly increase corporate revenues and facilitate further expansion. “In the next 12 months you won’t even recognize Lexaria,” Bunka states in the interview. “If you look at it today and look at where we are going to be in the next 12 months… I think we are going to be an entirely different company.” The full interview is available for review at http://nnw.fm/Lq94t.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Aug 14, 2017 4:35 pm

Regulation Forcing Drug and Cigarette Companies to Be More Responsible is Great News for Lexaria (LXRP), says CEO

In an interview with Stock Day, CEO Chris Bunka of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) discussed the company’s recent achievements and its plans for the near future. Revenues are climbing, exceeding, so far in 2017, the total for all of 2016, and the potential for further increases is imminent. The company is in negotiation with at least four large pharmaceutical companies to license its technology. The smallest of these could increase revenues by $1 million; the largest could increase revenues by much, much more, according to Bunka. Getting any of these deals signed will boost the bottom line almost as much as they would raise revenues. Lexaria will be employing a lucrative licensing model that is likely to yield 90-100% of revenues as profit. The company expects to have its first major agreement wrapped up by the end of the year.

Apart from attracting the attention of big pharma, Lexaria has been working with the National Research Council (NRC) of Canada, an agency of the Canadian federal government, to explore the effects of its technology. The company has developed technology that allows non-psychoactive cannabinoids, vitamins, non-steroid anti-inflammatory drugs (NSAIDs) and nicotine to be absorbed at much higher rates. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to 60-90 minutes for current methods, and is already in use in a number of consumer products.

Lexaria recently raised $4 million in capital. The company intends to spend part of the proceeds in setting up an R&D program for nicotine. The initiative comes at an opportune time. In August, the FDA announced “a new comprehensive plan for tobacco and nicotine regulation that will serve as a multi-year roadmap to better protect kids and significantly reduce tobacco-related disease and death” (http://nnw.fm/hLdm6). The agency plans to stimulate public dialogue on lowering nicotine levels in combustible cigarettes to non-addictive levels. This is good news for Lexaria, which is hoping its technology can provide a delivery method for nicotine that is safer than smoking. As its CEO has remarked, “Regulation is great news for Lexaria.”

The interview can be heard at http://nnw.fm/9QqQ8

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 491
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ


Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 1 guest

cron